

学校编码: 10384

分类号\_\_\_\_\_密级\_\_\_\_\_

学号: 21620060153298

UDC \_\_\_\_\_

廈門大學

博 士 学 位 论 文

四株植物内生真菌次级代谢产物的研究

The Study on the Secondary Metabolites from four  
Strains Endophytic Fungi

林挺

指导教师姓名: 沈月毛 教授

专 业 名 称: 微 生 物 学

论文提交日期: 2009 年 06 月

论文答辩时间: 2009 年 07 月

学位授予日期: 2009 年 月

答辩委员会主席: 831962\_\_\_\_\_

评 阅 人: \_\_\_\_\_

2009 年 07 月

# 厦门大学学位论文原创性声明

本人呈交的学位论文是本人在导师指导下,独立完成的研究成果。本人在论文写作中参考其他个人或集体已经发表的研究成果,均在文中以适当方式明确标明,并符合法律规范和《厦门大学研究生学术活动规范(试行)》。

另外,该学位论文为( )课题(组)的研究成果,获得( )课题(组)经费或实验室的资助,在( )实验室完成。(请在以上括号内填写课题或课题组负责人或实验室名称,未有此项声明内容的,可以不作特别声明。)

声明人(签名):

年 月 日

## 厦门大学学位论文著作权使用声明

本人同意厦门大学根据《中华人民共和国学位条例暂行实施办法》等规定保留和使用此学位论文，并向主管部门或其指定机构送交学位论文（包括纸质版和电子版），允许学位论文进入厦门大学图书馆及其数据库被查阅、借阅。本人同意厦门大学将学位论文加入全国博士、硕士学位论文共建单位数据库进行检索，将学位论文的标题和摘要汇编出版，采用影印、缩印或者其它方式合理复制学位论文。

本学位论文属于：

（        ） 1.经厦门大学保密委员会审查核定的保密学位论文，  
于        年        月        日解密，解密后适用上述授权。

（        ） 2.不保密，适用上述授权。

（请在以上相应括号内打“√”或填上相应内容。保密学位论文应是已经厦门大学保密委员会审定过的学位论文，未经厦门大学保密委员会审定的学位论文均为公开学位论文。此声明栏不填写的，默认为公开学位论文，均适用上述授权。）

声明人（签名）：

年        月        日

## 摘 要

植物内生菌作为一种新的微生物资源逐渐成为人们寻找新天然产物的热点。植物内生真菌作为植物内生菌的重要成员, 由于它的次级代谢产物往往种类繁多、骨架新颖、生物活性多样, 已成为发现新的生物活性物质的重要来源。

本论文以三种不同药用植物(滑桃树、喜树和番荔枝)为研究对象, 对来源于这三种药用植物的四株内生真菌(两株番荔枝植物内生真菌 *Pyrenochaeta* sp. B36、*Xylaria* sp. A45, 一株滑桃树植物内生真菌 *Aspergillus* sp. F1 和一株喜树内生真菌 *Phomopsis* sp. XZ26)的次级代谢产物进行分离纯化和结构鉴定。共分离并鉴定了 52 个化合物(包括 2 个乙酰化产物和 1 个乙酯化产物), 其中 23 个为新化合物(反应产物不属于新化合物), 对其中部分化合物进行抗菌、抗肿瘤活性研究。由于目前对这三种药用植物内生真菌的次级代谢产物的研究较少, 许多化合物都是首次从它们的内生真菌中分离得到。

从菌株 *Aspergillus* sp. F1 的次级代谢产物中分离并鉴定了 12 个化合物, 包括聚酮类化合物、萜类化合物、部分萜类化合物。其中 LT24 为新化合物, 命名为 butyl 3,5-dichloro-2-hydroxy-6-(2-hydroxy-4-methoxy-6-(methoxycarbonyl)phenoxy)-4-methylbenzoate; 新化合物 LT1 为部分萜类化合物, 命名为 butyrolactone-V。

运用核磁共振、质谱及 X-Ray 单晶衍射分析技术, 从菌株 *Phomopsis* sp. XZ26 的液体发酵和固体发酵产物中分离并鉴定了 14 个化合物, 包括 11 个聚酮(LTC, LTP, LTQ, LTJ-1, LTJ-2, LTG, LTH, 26-L-2, LTL, LTM, LTR)类化合物、2 个(LTA, LTO)萜类化合物和 1 个(LTD)大环内酯类化合物。其中化合物 LTC、LTG、LTH、LTJ-1、26-L-2、LTL、LTO、LTM、LTQ、LTR 为新化合物; 化合物 26-L-2, LTG, LTL, LTM 和 LTR 是首次从喜树内生真菌的次级代谢产物中分离得到, 对其中部分化合物进行了抗菌活性测定。结果表明, 这些化合物具有一定的抗菌活性。

从菌株 *Pyrenochaeta* sp. B36 的次级代谢产物中分离并鉴定了 8 个 (B36-1, LT-36-4, LT-36-9, LT-36-11, LT-36-15, LT-36-16, LT-36-17, LT-36-19)聚酮类化合物, 一个苯丙氨酸衍生物 LT-36-2, 一个对羟基苯甲醛聚合物 LT-36-12。其中化合物 LT-36-2, LT-36-12, LT-36-15, LT-36-16 和 LT-36-11 是新化合物, 且首次从番荔

枝内生真菌中分离得到。化合物 B36-1 是聚酮类化合物，有很强的抗肿瘤活性：在浓度为 5  $\mu\text{g/ml}$  时，对 Raji 细胞的抑制率为 82.21%；在浓度为 1.25  $\mu\text{g/ml}$  时，对 HEPG2 的抑制率为 49.79%。

在对番荔枝另外一株内生真菌 *Xylaria* sp. A45 的研究中，从其 PDA 平板发酵产物中共分离并鉴定了 13 个化合物，包括 9 个聚酮类化合物 (LT-45-1, LT-45-2, LT-45-4, LT-45-5, LT-45-7, LT-45-8, LT-45-10, LT-45-12, LT-45-14)、一个生物碱类化合物 (LT-45-24) 和三个萜类化合物 (LT-45-16, LT-45-21 和 LT-45-25)，其中 LT-45-2、LT-45-10、LT-45-16、LT-45-21、LT-45-25、LT-45-24 为新化合物。

本论文的结果表明，植物内生真菌作为植物生态一个重要的组成部分，其次级代谢产物具有结构新颖性与生物活性多样性的特征，是寻找药物先导化合物的重要资源。

**关键词：**药用植物；内生真菌；次级代谢产物

## Abstract

Recently, endophyte as a new microbiology resource has played an important role in people discovering novel natural products. Endophytic fungi is an important part of the endophyte, they can produce numerous secondary metabolites with several structures, novel skeletons and varied and high bioactivities. They have been a very important source for searching new bioactivity natural product over decades.

In this thesis, three medical plants (*Trewia nudiflora*, *Camptotheca acuminata*, *Annona squamosa* L.) were picked as research sources. The secondary metabolites of four endophytic strains of different plants (two strains *Pyrenochaeta* sp. B36 and *Xylaria* sp. A45 from *Annona squamosa* L., one strain *Aspergillus* sp. F1 from *Trewia nudiflora* and one strain *Phomopsis* sp. XZ26 from *Camptotheca acuminata* ) were investigated. Fifty two compounds were isolated and elucidated from these four strains, including twenty three new compounds. Partial compounds were tested for the antimicrobe and anticancer bioactivity. There were not many research about these medical plants's endophytic fungi, so many compounds were isolated for the first time.

Twelve compounds were isolated from the strain *Aspergillus* sp. F1. Their structures were elucidated by extensive spectroscopic data analyses, including polyketides, terpenoids and dibenzylbutyrolactone lignans. One of them was new polyketide, namely LT-24, named butyl 3,5-dichloro-2-hydroxy-6-(2-hydroxy-4-methoxy-6-(methoxycarbonyl)phenoxy)-4-methylbenzoate, another one was new dibenzylbutyrolactone lignan, namely LT1, named butyrolactone-V.

The secondary metabolites of the strain *Phomopsis* sp. XZ26 for both solid and liquid fermentations were studied. Fourteen compounds were isolated. Their structures were elucidated by extensive spectroscopic data analyses and X-ray crystallographic analysis, including eleven (LTC, LTP, LTQ, LTJ-1, LTJ-2, LTG, LTH, 26-L-2, LTL, LTM, LTR) polyketides, two (LTA, LTO) terpenoids and one (LTD) macrocyclic lactone. Among them, ten new compounds (LTC、LTD、LTG、LTH、LTJ-1、26-L-2、LTL、LTO、LTM、LTQ、LTR) were obtained. Except LTO was

monoterpen, the others were all new polyketides. Compounds 26-L-2, LTG, LTL, LTM and LTR were polyketides isolated from *Camptotheca acuminata* fungi for the first time. Some of the compounds were tested for anti-microbial activities. The result showed that they had humble activities against *Escherichia coli*, *Bacillus subtilis*, *Staphylococcus aureus*, *Sacharomyces cereviiae* and *Candidia albicans*.

Ten polyketides were isolated and identified from the strain *Pyrenochaeta* sp. B36 (B36-1, LT-36-2, LT-36-4, LT-36-9, LT-36-11, LT-36-12, LT-36-15, LT-36-16, LT-36-17, LT-36-19). LT-36-2, LT-36-12, LT-36-15, LT-36-16 and LT-36-11 were new compounds and they were isolated from *Annona squamosa* L. fungi for the first time. Compound B36-1 was polyketide. When tested with anticancer bioactivity, this compound exhibited very strong activity. At the concentration of 5 $\mu$ g/ml, it still has 82.21% inhibition rate against the Raji cell. When tested against HEPG2 cell, at the concentration 1.25 $\mu$ g/ml, it still showed inhibition rate at 49.79%.

From another *Annona squamosa* L.'s endophytic fugus *Xylaria* sp. A45, thirteen compounds were obtained, including nine polyketides (LT-45-1, LT-45-2, LT-45-4, LT-45-5, LT-45-7, LT-45-8, LT-45-10, LT-45-12, LT-45-14), three new steroids (LT-45-16, LT-45-21 and LT-45-25) and one alkoid (LT-45-24). Compounds LT-45-2, LT-45-10, LT-45-16, LT-45-21 and LT-45-25 were new compounds.

In conclusion, this thesis indicated that endophytic fungi, this important part of plant system, contain novel and bioactive compounds in its secondary metabolisms. It is an important source for searching lead compounds for drugs.

**Key words:** Medical plant; Endophytic fungi; Secondary metabolisms

## Catalogue

<b>Abstract</b> .....	<b>I</b>
<b>Abstract in English</b> .....	<b>III</b>
<b>Introduction</b> .....	<b>1</b>
<b>1 Advance on plant endophyte</b> .....	<b>1</b>
<b>2 Advance on secondary metabolites from plant endophyte fungi</b> .....	<b>2</b>
<b>2.1 Plant Endophytic fungi</b> .....	<b>2</b>
<b>2.2 Secondary metabolites from Plant endophytic fungi</b> .....	<b>2</b>
2.2.1 Antimicrobial compounds .....	2
2.2.2 Antitumor compounds .....	8
2.2.3 Compounds with Anti-HIV activity .....	18
2.2.4 Compounds with insecticidal activity .....	22
2.2.5 Enzyme inhibitor .....	23
2.2.6 New compounds without bioactivity .....	24
<b>3 Secondary metabolites from <i>Trewia nudiflora</i>'s endophytic fungi</b> .....	<b>26</b>
<b>4 Secondary metabolites from <i>Camptotheca acuminata</i>'s endophytic fungi</b> .....	<b>28</b>
<b>5 Secondary metabolites from <i>Annona squamosa</i> L's endophytic fungi</b> .....	<b>29</b>
<b>6 Purpose, contents and significance of this thesis</b> .....	<b>30</b>
<b>Materials and methods</b> .....	<b>32</b>
<b>1 Materials</b> .....	<b>32</b>
<b>2 Methods</b> .....	<b>36</b>
<b>Results and analysis</b> .....	<b>43</b>
<b>一、 The isolation and identification of strain F1</b> .....	<b>43</b>
<b>二、 The study of secondary metabolites from the strain F1</b> .....	<b>43</b>
<b>1 The solid fermentation and extraction</b> .....	<b>43</b>
<b>2 The isolation of metabolites</b> .....	<b>43</b>



2.1 The isolation of fraction 50% .....	44
2.2 The isolation of fraction 70% .....	47
<b>3 The elucidation of compound's structure .....</b>	<b>49</b>
3.1 Compound LT1 .....	50
3.2 Compound LT35 .....	52
3.3 Compound LT4 .....	54
3.4 Compound LT29 .....	55
3.5 Compound LT17 .....	56
3.6 Compound LT36 .....	57
3.7 Compound LT27P .....	58
3.8 Compound LT25 .....	59
3.9 Compound LT37 .....	60
3.10 Compound LT33 .....	61
3.11 Compound LT23 .....	62
3.12 Compound LT24 .....	63
<b>4 The antitumor activity of compound LT17 and compound LT29 .....</b>	<b>64</b>
<b>三、 The study of secondary metabolites from the strain XZ26 .....</b>	<b>64</b>
<b>1 The solid fermentation and extraction .....</b>	<b>65</b>
<b>2 The isolation of metabolites .....</b>	<b>65</b>
2.1 The isolation of EA exaction of fermentation .....	66
<b>3 The liquid fermentation and extraction .....</b>	<b>68</b>
<b>4 The isolation of metabolites .....</b>	<b>68</b>
4.1 The isolation of fraction EA-13 .....	69
<b>5 The elucidation of compound's structure .....</b>	<b>69</b>
5.1 Compound LTA .....	70
5.2 Compound LTQ .....	73
5.3 Compound LTH .....	75
5.4 Compound LTC .....	76
5.5 Compound LTP .....	77
5.6 Compound LT-J-2 .....	78

5.7 Compound LT-J-1 .....	79
5.8 Compound 26-L-2 .....	79
5.9 Compound LTG .....	80
5.10 Compound LTM .....	82
5.11 Compound LTL .....	83
5.12 Compound LTR .....	83
5.13 Compound LTO .....	84
5.14 Compound LTD .....	85
<b>6 The antimicrobial activity of compounds LTQ, LTH, LTC, LTP, LTJ-1, LTJ-2, LTG, LTL, LTO and LTA .....</b>	<b>86</b>
<b>四、 The study of secondary metabolites from the strain A45 .....</b>	<b>87</b>
<b>1 The solid fermentation and extraction .....</b>	<b>87</b>
<b>2 The isolation of metabolites .....</b>	<b>87</b>
2.1 The isolation of fraction 1 .....	87
2.2 The isolation of fraction 2 .....	88
2.3 The isolation of fraction 3 .....	89
2.4 The isolation of fraction 6 .....	89
2.5 The isolation of fraction 5 .....	90
<b>3 The elucidation of compound's structure .....</b>	<b>92</b>
3.1 Compound LT-45-1 .....	93
3.2 Compound LT-45-5 .....	94
3.3 Compound LT-45-2 .....	95
3.4 Compound LT-45-4 .....	96
3.5 Compound LT-45-7 .....	96
3.6 Compound LT-45-8 .....	97
3.7 Compound LT-45-10 .....	98
3.8 Compound LT-45-12 .....	99
3.9 Compound LT-45-14 .....	100
3.10 Compound LT-45-24 .....	101
3.11 Compound LT-45-21 .....	101

3.12 Compound LT-45-25 .....	103
3.13 Compound LT-45-16 .....	105
<b>4 Compound's bioactivity.....</b>	<b>107</b>
<b>五、 The study of secondary metabolites from the strain B36.....</b>	<b>107</b>
<b>1 The liquid fermentation and extraction.....</b>	<b>107</b>
<b>2 The isolation of fraction Me .....</b>	<b>108</b>
<b>3 The second time liquid fermentation and extraction.....</b>	<b>109</b>
3.1 The isolation of fraction B36second Cout .....	109
3.2 The isolation of fraction B36second Cin .....	110
<b>4 The third time liquid fermentation and extraction.....</b>	<b>110</b>
4.1 The isolation of fraction B36third Cout.....	110
4.2 The isolation of fraction B36third Cin.....	111
<b>5 The time screening experiment for strain B36's liquid fermentation .....</b>	<b>112</b>
<b>6 The solid fermentation and extraction.....</b>	<b>113</b>
6.1 The isolation of fraction EA .....	113
<b>7 The solid fermentation and extraction.....</b>	<b>117</b>
7.1 The isolation of fraction EA .....	117
<b>8 The media screening experiment for stain B36's fermentation .....</b>	<b>118</b>
<b>9 The solid fermentation and extraction.....</b>	<b>119</b>
9.1 The isolation of metabolites .....	120
9.1.1 The isolation of fraction a.....	120
9.1.2 The isolation of fractions b and c.....	120
9.1.3 The isolation of fraction d .....	122
9.1.4 The isolation of fraction f.....	122
9.1.5 The isolation of fraction f-2'.....	123
<b>10 The elucidation of compound's structure .....</b>	<b>125</b>
10.1 Compound LT-36-2 .....	126
10.2 Compound LT-36-4 .....	127
10.3 Compound LT-36-9 .....	128
10.4 Compound LT-36-12 .....	129

10.5 Compound LT-36-15 .....	130
10.6 Compound LT-36-16 .....	132
10.7 Compound LT-36-17 .....	133
10.8 Compound LT-36-19 .....	135
10.9 Compound LT-36-11 .....	136
10.10 Compound B36-1 .....	137
<b>11 The antitumor activities of compounds .....</b>	<b>138</b>
<b>Discussion and conclusion .....</b>	<b>139</b>
<b>一、 Polyketides .....</b>	<b>139</b>
1.1 Polyketides from strain F1 .....	140
1.2 Polyketides from strain XZ26 .....	141
1.3 Polyketides from strain A45 .....	142
1.3.1 Compound LT-45-2 .....	142
1.3.2 Compound LT-45-10 .....	142
1.3.3 Compound LT-45-14 .....	143
1.4 Polyketides from strain B36 .....	143
<b>二、 Terpenoid .....</b>	<b>144</b>
1.1 Terpenoids from strain F1 .....	144
1.2 Terpenoids from strain XZ26 .....	145
1.3 Terpenoids from strain A45 .....	145
<b>三、 Conclusion .....</b>	<b>146</b>
<b>四、 Expectation .....</b>	<b>146</b>
<b>Abbreviations of English .....</b>	<b>148</b>
<b>References .....</b>	<b>150</b>
<b>Acknowledgements .....</b>	<b>157</b>

## 目 录

摘 要.....	I
Abstract.....	III
第一篇 前 言 .....	1
1. 植物内生菌的研究概况.....	1
2. 植物内生真菌次级代谢产物的研究概况.....	2
2.1. 植物内生真菌 .....	2
2.2. 植物内生真菌次级代谢产物 .....	2
2.2.1. 抗菌活性化合物.....	2
2.2.2. 抗肿瘤活性化合物.....	8
2.2.3. 抗 HIV 活性化合物 .....	18
2.2.4. 抗虫活性化合物.....	22
2.2.5. 酶抑制剂.....	23
2.2.6. 未有活性报道的新化合物.....	24
3. 滑桃树内生真菌的次级代谢产物.....	26
4. 喜树内生真菌的次级代谢产物.....	28
5. 番荔枝内生真菌的次级代谢产物.....	29
6. 本课题研究的目的、内容和意义.....	30
第二篇 材料与方法 .....	32
一、材料.....	32
1. 菌株来源 .....	32
2. 拮抗测定指示菌 .....	32
3. 肿瘤细胞株 .....	32
4. 常用试剂 .....	32
5. 常用培养基 .....	33
6. 主要试剂及耗材 .....	34
7. 主要仪器 .....	35
二、方法.....	36

<b>1. 技术路线 .....</b>	<b>36</b>
<b>2. 生物活性的测定 .....</b>	<b>36</b>
2.1. 抗菌活性测定 .....	36
2.2. 肿瘤细胞培养 .....	37
2.3. 抗肿瘤活性测定 .....	37
2.4. 菌株的发酵 .....	38
2.5. 天然产物的分离纯化 .....	38
2.5.1. 薄层层析 (TLC) .....	38
2.5.2. 反相硅胶柱 (RP-18)层析 .....	39
2.5.3. 凝胶柱 Sephadex LH-20 层析 .....	39
2.5.4. 正相硅胶柱层析 .....	39
2.5.5. 高效液相色谱 (HPLC) .....	40
2.5.6. 重结晶 .....	40
2.6. 化合物的结构鉴定 .....	41
2.6.1. 质谱分析 .....	41
2.6.2. 核磁共振分析 .....	41
2.6.3. X-Ray 单晶衍射分析 .....	41
2.6.4. 紫外吸收波长及红外测定 .....	41
2.6.5. 旋光测定 .....	41
<b>第三篇 结果与分析 .....</b>	<b>43</b>
<b>一. F1 菌株的分离和鉴定 .....</b>	<b>43</b>
<b>二. F1 菌株次级代谢产物的研究 .....</b>	<b>43</b>
1. 菌株的固体发酵及发酵产物的处理 .....	43
2. 发酵产物的分离纯化 .....	43
2.1. 50%组分的分离纯化 .....	44
2.2. 70%组分的分离纯化 .....	47
<b>3. 化合物的结构解析 .....</b>	<b>49</b>
3.1. 化合物 LT1 .....	50
3.2. 化合物 LT35 .....	52

3.3. 化合物 LT4 .....	54
3.4. 化合物 LT29 .....	55
3.5. 化合物 LT17 .....	56
3.6. 化合物 LT36 .....	57
3.7. 化合物 LT27P .....	58
3.8. 化合物 LT25 .....	59
3.9. 化合物 LT37 .....	60
3.10. 化合物 LT33 .....	61
3.11. 化合物 LT23 .....	62
3.12. 化合物 LT24 .....	63
4. 化合物 LT17 和 LT29 的抗肿瘤活性测试 .....	64
三、喜树内生真菌 XZ-26 菌株次级代谢产物的研究 .....	64
1. 菌株的固体发酵及发酵产物的处理 .....	65
2. 喜树内生真菌 XZ-26 的发酵产物的乙酸乙酯相次生代谢产物的分离纯化 .....	65
2.1. 乙酸乙酯相化合物的分离纯化 .....	66
3. XZ-26 菌株的静置发酵及发酵产物的处理 .....	68
4. 静置发酵产物的分离纯化 .....	68
4.1. EA-13 组分的分离纯化 .....	69
5. 化合物的结构解析 .....	69
5.1. 化合物 LTA .....	70
5.2. 化合物 LTQ .....	73
5.3. 化合物 LTH .....	75
5.4. 化合物 LTC .....	76
5.5. 化合物 LTP .....	77
5.6. 化合物 LT-J-2 .....	78
5.7. 化合物 LT-J-1 .....	79
5.8. 化合物 26-L-2 .....	79
5.9. 化合物 LTG .....	80

5.10. 化合物 LTM .....	82
5.11. 化合物 LTL .....	83
5.12. 化合物 LTR .....	83
5.13. 化合物 LTO .....	84
5.14. 化合物 LTD .....	85
<b>6. 化合物 LTQ,LTH, LTC,LTP,LTJ-1,LTJ-2,LTG,RTL,LTO 和 LTA 的抗 菌活性 .....</b>	<b>86</b>
<b>四、A45 菌株次级代谢产物的研究.....</b>	<b>87</b>
1. 菌株的固体发酵及发酵产物的处理 .....	87
2. 发酵产物的分离纯化 .....	87
2.1. 组分 1 的分离纯化 .....	87
2.2. 组分 2 的分离纯化 .....	88
2.3. 组分 3 的分离纯化 .....	89
2.4. 组分 6 的分离纯化 .....	89
2.5. 组分 5 的分离纯化 .....	90
3. 化合物的结构解析 .....	92
3.1. 化合物 LT-45-1 .....	93
3.2. 化合物 LT-45-5 .....	94
3.3. 化合物 LT-45-2 .....	95
3.4. 化合物 LT-45-4 .....	96
3.5. 化合物 LT-45-7 .....	96
3.6. 化合物 LT-45-8 .....	97
3.7. 化合物 LT-45-10 .....	98
3.8. 化合物 LT-45-12 .....	99
3.9. 化合物 LT-45-14 .....	100
3.10. 化合物 LT-45-24 .....	101
3.11. 化合物 LT-45-21 .....	101
3.12. 化合物 LT-45-25 .....	103
3.13. 化合物 LT-45-16 .....	105



Degree papers are in the "[Xiamen University Electronic Theses and Dissertations Database](#)". Full texts are available in the following ways:

1. If your library is a CALIS member libraries, please log on <http://etd.calis.edu.cn/> and submit requests online, or consult the interlibrary loan department in your library.
2. For users of non-CALIS member libraries, please mail to [etd@xmu.edu.cn](mailto:etd@xmu.edu.cn) for delivery details.

厦门大学博硕士论文摘要库